UTime Limited Explores Application of AI Technology in Health Data Analysis
UTime (Nasdaq: WTO) announced ongoing research into applying AI to health data analysis from wearable devices on November 3, 2025. The company is developing AI algorithm models to analyze continuous physiological signals from smart watches and rings.
Key research directions include building hypertension risk assessment models that integrate blood pressure, heart rate, activity and sleep, and conducting cardiovascular trend assessments via pulse wave morphology analysis. UTime says these AI functions are intended as health insights and risk-management references, not medical diagnoses. Management framed the work as a long-term R&D investment to generate earlier, deeper user health insights.
UTime (Nasdaq: WTO) ha annunciato la ricerca in corso sull'applicazione AI all'analisi dei dati sanitari provenienti da dispositivi indossabili al 3 novembre 2025. L'azienda sta sviluppando modelli di algoritmi di AI per analizzare segnali fisiologici continui provenienti da orologi intelligenti e anelli.
Le direzioni chiave della ricerca includono la costruzione di modelli di valutazione del rischio di ipertensione che integrano pressione sanguigna, frequenza cardiaca, attività e sonno, e la conduzione di valutazioni delle tendenze cardiovascolari tramite l'analisi della morfologia dell'onda di polso. UTime afferma che queste funzioni AI sono destinate a insight sanitari e riferimenti per la gestione del rischio, non a diagnosi mediche. La direzione è presentata come un investimento di Ricerca e Sviluppo a lungo termine per generare intuizioni sulla salute degli utenti in modo più precoce e approfondito.
UTime (Nasdaq: WTO) anunció investigaciones en curso sobre la aplicación de IA al análisis de datos de salud provenientes de dispositivos ponibles en 3 de noviembre de 2025. La empresa está desarrollando modelos de algoritmos de IA para analizar señales fisiológicas continuas de smartwatches y anillos.
Las direcciones clave de la investigación incluyen construir modelos de evaluación de riesgo de hipertensión que integren la presión arterial, la frecuencia cardíaca, la actividad y el sueño, y realizar evaluaciones de tendencias vasculares mediante el análisis de la morfología de la onda de pulso. UTime dice que estas funciones de IA están pensadas como informes de salud y referencias para la gestión del riesgo, no como diagnósticos médicos. La dirección describe el trabajo como una inversión de I+D a largo plazo para generar insights de salud de los usuarios de forma más temprana y profunda.
UTime (나스닥: WTO)는 AI를 웨어러블 기기의 건강 데이터 분석에 적용하는 연구를 2025년 11월 3일에 진행 중이라고 발표했습니다. 회사는 스마트워치와 반지에서 나오는 연속적인 생리 신호를 분석하기 위한 AI 알고리즘 모델을 개발 중입니다.
연구의 주요 방향으로는 혈압, 심박수, 활동량, 수면을 통합하는 고혈압 위험 평가 모델을 구축하고 맥파 형태 분석을 통한 심혈관 추세 평가를 수행하는 것이 포함됩니다. UTime은 이러한 AI 기능이 건강 인사이트 및 위험 관리 참조로 의도되었으며 진단 의학적 진단이 아니라고 말합니다. 경영진은 이를 더 빠르고 깊은 사용자 건강 인사이트를 창출하기 위한 장기 R&D 투자로 설명했습니다.
UTime (Nasdaq : WTO) a annoncé des recherches en cours sur l'application de l'IA à l'analyse des données de santé issues de dispositifs portables le 3 novembre 2025. L'entreprise développe des modèles d'algorithmes d'IA pour analyser les signaux physiologiques continus provenant des montres intelligentes et des anneaux.
Les directions clés de la recherche incluent la construction de modèles d'évaluation du risque d'hypertension qui intègrent la pression artérielle, la fréquence cardiaque, l'activité et le sommeil, et la réalisation d'évaluations des tendances cardiovasculaires via l'analyse de la morphologie de l'onde de pouls. UTime indique que ces fonctions d'IA sont destinées à fournir des informations de santé et des références pour la gestion du risque, et non à des diagnostics médicaux. La direction présente ce travail comme un investissement à long terme en R&D pour générer des informations sur la santé des utilisateurs plus précoces et plus approfondies.
UTime (Nasdaq: WTO) kündigte laufende Forschungen an, um KI auf die Analyse von Gesundheitsdaten aus tragbaren Geräten anzuwenden, am 3. November 2025. Das Unternehmen entwickelt KI-Algorithmusmodelle, um kontinuierliche physiologische Signale von Smartwatches und Ringen zu analysieren.
Zu den wichtigsten Forschungsrichtungen gehört der Aufbau von Hypertension risk assessment models, die Blutdruck, Herzfrequenz, Aktivität und Schlaf integrieren, sowie die Durchführung von kardiovaskulären Trendbewertungen über die Analyse der Morphologie der Pulswelle. UTime erklärt, dass diese KI-Funktionen als Gesundheits-Insights und Referenzen für Risikomanagement gedacht sind und keine medizinischen Diagnosen darstellen. Das Management bezeichnet die Arbeit als eine langfristige F&E-Investition, um frühere, tiefere Einblicke in die Gesundheit der Nutzer zu gewinnen.
UTime (Nasdaq: WTO) أعلنت عن أبحاث جارية في تطبيق الذكاء الاصطناعي على تحليل بيانات الصحة من أجهزة قابلة للارتداء في 3 نوفمبر 2025. الشركة تطوّر نماذج خوارزميات AI لتحليل الإشارات الفسيولوجية المستمرة من ساعات ذكية وخواتم.
تشمل اتجاهات البحث الأساسية بناء نماذج تقييم مخاطر ارتفاع ضغط الدم التي تدمج الضغط الدموي، معدل ضربات القلب، النشاط والنوم، وإجراء تقييمات الاتجاهات القلبية الوعائية عبر تحليل مورفولوجيا موجة النبض. تقرر UTime أن هذه الوظائف AI مخصصة ك< b>إرشادات صحية ومراجع لإدارة المخاطر، وليست تشخيصات طبية. وصف الإدارة العمل بأنه استثمار بحث وتطوير طويل الأجل لتوليد رؤى صحية أكثر قدرة وباكرة للمستخدمين.
- None.
- None.
SHENZHEN, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- UTime Limited (Nasdaq: WTO) today outlined its ongoing exploration in the field of health data analysis, particularly the potential application of artificial intelligence (AI) technologies.
UTime is developing AI-based algorithm models aimed at performing in-depth analysis of continuous physiological data collected from smart wearable devices such as watches and rings. Current research directions include: building hypertension risk assessment models by integrating multi-parameter data like blood pressure, heart rate, activity and sleep; and conducting trend assessments of users' cardiovascular system health status by analyzing features such as pulse wave morphology. The company explicitly states that all these AI analysis functions are intended to provide users with health trend insights and risk management references and are not substitutes for professional medical diagnosis.
Mr. Hengcong Qiu, Chief Executive Officer of UTime Limited, stated, "Data itself is not the end goal. Our R&D focus is on how to generate deeper insights from the data, helping users understand their own health trends earlier. This is the direction of our long-term technological investment."
About UTime Limited
Trading under the NASDAQ ticker WTO, UTime Limited is engaged in the design, development, production, sales and brand operation of mobile devices in China and globally. The company aims to provide cost-effective products and serves a broad customer base.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. For additional risk factors, please review UTime Limited’s Annual Report on Form 20-F and other SEC filings. Forward-looking statements are made only as of the date of this release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required under applicable law.
Contact:
qhengcong@utimemobile.com
UTime Limited
7th Floor, Building 5A
Shenzhen Software Industry Base, Nanshan District
Shenzhen, People’s Republic of China 518061
Tel: (86) 755 86512266
Attachments
FAQ
What AI health analytics did UTime (WTO) announce on November 3, 2025?
Which wearable data types will UTime (WTO) use for its AI hypertension risk models?
Does UTime (WTO) claim its AI tools replace medical diagnosis?
What cardiovascular feature will UTime (WTO) analyze with AI?
How did UTime (WTO) describe its R&D focus on AI and health data?
Which devices are the source of data for UTime's (WTO) AI research?
